TLR4 Agonist MPLA Ameliorates Heavy-Ion Radiation Damage via Regulating DNA Damage Repair and Apoptosis
Radiation Research · 06.06.2023 · 200 (2) · 127-138
DOI: 10.1667/rade-22-00200.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Research, erschienen am 06.06.2023. Verfasst von Tingting Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Radiation Injuries, Toll-Like Receptor 4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Heavy-ion radiation received during radiotherapy as well as the heavy-ion radiation received during space flight are equally considered harmful. Our previous study showed that TLR4 low toxic agonist, monophosphoryl lipid A (MPLA), alleviated radiation injury resulting from exposure to low-LET radiation. However, the role and mechanism of MPLA in heavy-ion-radiation injury are unclear. This study aimed to investigate the role of MPLA on radiation damage. Our data showed that MPLA treatment alleviated the heavy-ion-induced damage to microstructure and the spleen and testis indexes. The number of karyocytes in the bone marrow from the MPLA-treated group was higher than that in the irradiated group. Meanwhile, western blotting analysis of intestine proteins showed that pro-apoptotic proteins (cleaved-caspase3 and Bax) were downregulated while anti-apoptotic proteins (Bcl-2) were upregulated in the MPLA-treated group. Our in vitro study demonstrated that MPLA significantly improved cell proliferation and inhibited cell apoptosis after irradiation. Moreover, immunofluorescence staining and quantification of nucleic γ-H2AX and 53BP1 foci also suggested that MPLA significantly attenuated cellular DNA damage repair. Collectively, the above evidence supports the potential ability of MPLA to protect against heavy-ion-radiation injury by inhibiting apoptosis and alleviating DNA damage in vivo and vitro, which could be a promising medical countermeasure for the prevention of heavy-ion-radiation injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China.
- School of Public Health and Management, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, 325035, China.
- Pharmacy Department, Qingdao Special Servicemen Recuperation Center of CPLA Navy, Qingdao 266071, China.
Zitieren
APA
Liu, T., Wang, H., Shen, H., Du, Z., Wan, Z., Li, J., Zhang, X., Li, Z., Yang, N., Yang, Y., Chen, Y., Gao, F., & Cao, K. (2023). TLR4 Agonist MPLA Ameliorates Heavy-Ion Radiation Damage via Regulating DNA Damage Repair and Apoptosis. Radiation Research, 200(2), 127-138. https://doi.org/10.1667/rade-22-00200.1
Vancouver
Liu T, Wang H, Shen H, Du Z, Wan Z, Li J, et al. TLR4 Agonist MPLA Ameliorates Heavy-Ion Radiation Damage via Regulating DNA Damage Repair and Apoptosis. Radiation Research. 2023;200(2):127-138. doi:10.1667/rade-22-00200.1
BibTeX
@article{Liu2023,
author = {Liu, Tingting and Wang, Hang and Shen, Hui and Du, Zhipeng and Wan, Zhijie and Li, Junshi and Zhang, Xide and Li, Zhuqing and Yang, Nan and Yang, Yanyong and Chen, Yuanyuan and Gao, Fu and Cao, Kun},
title = {TLR4 Agonist MPLA Ameliorates Heavy-Ion Radiation Damage via Regulating DNA Damage Repair and Apoptosis},
journal = {Radiation Research},
year = {2023},
volume = {200},
number = {2},
pages = {127--138},
doi = {10.1667/rade-22-00200.1}
}
EUVIMED